Kontafarma China Holdings (HKG:1312) expects a consolidated net loss between HK$79.2 million and HK$118.8 million in 2024, wider than the HK$61.1 million net loss in 2023, a Tuesday Hong Kong bourse filing said.
The pharmaceutical company attributed the anticipated increase to an impairment recognized on intangible assets associated with its fitness business, as well as the absence of a one-time gain from the disposal of subsidiaries, which had been recorded during the same period last year.
Shares of the company were down nearly 7% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。